8-K ·Filed Aug 3, 2026

AUTL

Autolus Therapeutics plc
NEUTRAL
Impact 6/10
Horizonmonths Processed2mo ago SEC0001193125-26-329526
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

The $75M initial draw provides immediate liquidity to fund obe-cel commercialization, but the debt structure with revenue-based covenants creates a binary catalyst path — successful AUCATZYL launch triggers access to additional $175M capacity and lower interest rates, while missing revenue targets could trigger liquidity constraints. Monitor obe-cel launch metrics and next quarterly revenue disclosure for covenant compliance signals.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+20d ⚠ clustered
AUTL ▲ +29.12% at T+20d
NEUTRAL call ✓ call won +29.12% · α vs SPY +27.88% · entry $1.82 → $2.35
Next anchor: T+60d in 25d
Latest observation: T+39 +10.72% FF3 residual α
Entry anchored
Jul 31, 04:00 PM ET
via exchange tick
T+1d
+7.14%
call +7.14% · α +5.34%
$1.95
settled 8w ago
T+5d
+13.74%
call +13.74% · α +11.71%
$2.07
settled 8w ago
T+20d
+29.12%
call +29.12% · α +27.88%
$2.35
settled 5w ago
T+60d
—
call — · α —
—
in 25d

Price Chart

Loading chart...

Executive Summary

Autolus Therapeutics entered into a $250M senior secured notes facility with Perceptive Credit Holdings, issuing an initial $75M tranche on July 30, 2026. The facility includes up to $175M in additional tranches contingent on revenue milestones, carries interest at SOFR + 6.75%-7.25%, and matures July 30, 2031. Concurrently, Autolus issued Perceptive a warrant for 3.5M ADSs at $1.9314/share (125% of 30-day VWAP) and entered into a registration rights agreement. The transaction provides significant non-dilutive capital to fund commercialization of obe-cel (AUCATZYL) but adds substantial debt with financial covenants requiring minimum liquidity ($12.5M-$50M) and minimum consolidated net revenue targets.

Key Financial Metrics

Deal Value
$250.0M
Deal Type
credit_facility
Offering Size
$75.0M

Key Facts

  • Autolus entered a $250M senior secured notes facility with Perceptive Credit Holdings V, LP
  • Initial $75M tranche (Tranche 1) funded on July 30, 2026
  • Up to $175M additional capacity across Tranche 2 ($25M), Tranche 3 ($75M), and Tranche 4 ($75M)
  • Tranche 3 and 4 availability conditioned on achieving undisclosed Consolidated Net Revenue thresholds
  • Interest rate: 1-month Term SOFR (floor 3.50%) + 6.75%-7.25% margin, stepping down with revenue milestones
  • Maturity date: July 30, 2031; no scheduled principal amortization
  • Early redemption premiums: 8% (yr 1), 6% (yr 2), 3% (yr 3), 2% (yr 4), 1% thereafter
  • Issued warrant to Perceptive for 3,500,000 ADSs at $1.9314/share (125% of 30-day VWAP)
  • Additional warrants for 2,500,000 ADSs each upon Tranche 3 and Tranche 4 issuances
  • All warrants expire July 30, 2036; cashless exercise and automatic exercise features
  • Financial covenants: minimum liquidity ($12.5M-$50M) and minimum consolidated net revenue (amounts redacted)
  • Obligations secured by first-priority liens on substantially all assets of Autolus and subsidiary guarantors
  • Registration rights agreement requires filing resale registration statement within 45 days of closing

Financial Impact

$250M senior secured notes facility with $75M initial draw; warrants for up to 8.5M ADSs at $1.9314/share (initial tranche)

debtdilutionliquiditycash

Risk Factors

  • Revenue covenant risk — failure to meet undisclosed Consolidated Net Revenue thresholds could restrict access to Tranche 3/4 funding and trigger default
  • Dilution risk from warrants — full exercise of all warrants would add up to 8.5M ADSs (approximately 8-10% dilution based on current shares outstanding)
  • Interest rate exposure — floating rate with 3.50% SOFR floor means rising rates increase debt service costs
  • Early redemption premiums (up to 8%) create refinancing disincentive in early years
  • First-lien secured structure subordinates existing unsecured creditors

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-329526
Document: d156965dex102.htm0001193125-26-329526
Document: d156965dex41.htm0001193125-26-329526
Document: d156965d8k.htm0001193125-26-329526
Document: 0001193125-26-329526-index-headers.html0001193125-26-329526
13 reports for AUTL
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+20▲ +29.12%Aug 3, 2026
Filters
Rows
Reports for AUTL — sortable, filterable
TypeNow
Sep 12, 2026
20d ago
S-3
NEUTRAL ★ 4/10
$1.94 $1.94· 0.00%▼ −0.11%$1.78 (−8.25%)
Aug 11, 2026
7w ago
8-K
BULLISH ★ 7/10
$2.33 $2.29▼ −1.72%▼ −1.31%$1.78 (−23.61%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$1.82 $2.07▲ +13.74%▲ +11.71%$1.78 (−2.20%)
Aug 3, 2026
8w ago
8-K
NEUTRAL ★ 6/10
$1.82 $2.07▲ +13.74%▲ +11.71%$1.78 (−2.20%)
Jun 12, 2026
16w ago
Press Release
NEUTRAL ★ 3/10
$1.56 $1.51▼ −3.21%▼ −3.88%$1.78 (+14.10%)
Jun 11, 2026
16w ago
Institutional Cluster
BEARISH ★ 6/10
$1.56 $1.53▲ +1.92%▲ +2.36%$1.78 (−14.10%)
Jun 9, 2026
16w ago
8-K
BEARISH ★ 7/10
$1.46 $1.50▼ −2.74%▼ −0.33%$1.78 (−21.92%)
May 21, 2026
19w ago
Press Release
NEUTRAL ★ 4/10
$1.70 $1.84▲ +8.24%▲ +6.58%$1.78 (+4.71%)
May 14, 2026
20w ago
8-K
MIXED ★ 6/10
$1.59 $1.65▲ +3.77%▲ +4.49%$1.78 (+11.95%)
May 14, 2026
20w ago
Press Release
MIXED ★ 6/10
$1.59 $1.65▲ +3.77%▲ +4.49%$1.78 (+11.95%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (38h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access